Details for Patent: 8,785,500

Which drugs does patent 8,785,500 protect, and when does it expire?

Patent 8,785,500 protects SPRAVATO and is included in one NDA.

This patent has six patent family members in six countries.

Summary for Patent: 8,785,500

Patent landscape, scope, and claims:

Title:	Intranasal administration of ketamine to treat depression
Abstract:	Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).
Inventor(s):	Charney; Dennis S. (Chappaqua, NY), Mathew; Sanjay J. (New York, NY), Manji; Husseini K. (Rockville, MD), Zarate, Jr.; Carlos A. (Germantown, MD), Krystal; John H. (Woodbridge, CT)
Assignee:	Icahn School of Medicine at Mount Sinai (New York, NY) Yale University (New Haven, CT) National Institute of Health (Rockville, MD)
Application Number:	11/688,603
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 8,785,500

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Janssen Pharms	SPRAVATO	esketamine hydrochloride	SPRAY;NASAL	211243-001	Mar 5, 2019		RX	Yes	Yes						TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULT IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT

International Family Members for US Patent 8,785,500

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007229866
China	101466364
European Patent Office	2012762
Japan	2009530385
South Korea	20090029690